Developing Nanodosing of Iobenguane I 131 for Radiotherapy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44CA115120-02
Agency Tracking Number: CA115120
Amount: $925,243.00
Phase: Phase II
Program: SBIR
Awards Year: 2006
Solicitation Year: 2006
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Small Business Information
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
MOLECULAR INSIGHT PHARMACEUTICALS, INC., 160 SECOND ST, CAMBRIDGE, MA, 02142
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JAMES KRONAUGE
 (617) 492-5554
 jkronauge@molecularinsight.com
Business Contact
 OLGA LEGOCKI
Phone: (617) 492-5554
Email: olegocki@molecularinsight.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This Phase 2 SBIR is for the development of a drug product identified and demonstrated in the Phase 1 SBIR award (R43CA15120-01). The ultimate goal is to produce, sell and deliver doses of high specific activity iobenguane I 131 for radiotherapy in adults and children with neuroendocrine tumors. These are rare tumors with only about 800 cases a year in the US but with poor outcome and no approved effective treatment. The innovation in this proposal is that it uses a solid phase synthetic process to make a proven diagnostic agent in a radio-therapeutic quantity (1 Curie) without the pharmacologically active carrier compound. A type B pre-IND development was held with the FDA where they definitively stated that USP test methods are insufficient to permit human testing of iobenguane I 131 produced by a new method. However, the FDA concluded that literature reports indicate iobenguane I 131 therapy is efficient for treating neuroendocrine tumors and granted Orphan Drug and Fast Tract status for the development of high specific activity drug product. To meet the required quality control of components of the chemistry, manufacturing and controls component of a IND application, the polymer supported drug precursor will be produced according to current good manufacturing practices and analytical tests developed and validated to confirm the identity, purity, performance and impurity profile of the critical component drug precursor. We will also develop a Drug Master File and execute batch records for the production process of the radioactive drug substance. Finally batches of the final drug product will be made and tested for stability and bio-equivalence in transporter expressing cells and in animals.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government